BRAF and melanoma: This was also observed in patients with PD-L1-negative and -positive melanomas and across subgroups according to baseline characteristics (sex, age, ulceration, BRAF mutation status, lymph node involvement), similar to that in the ITT population (also between patients with both AJCC-7 and AJCC-8 staging).